Protagonist Therapeutics is a company.
Protagonist Therapeutics has raised $54.0M across 2 funding rounds.
Key people at Protagonist Therapeutics.
Protagonist Therapeutics has raised $54.0M in total across 2 funding rounds.
Protagonist Therapeutics has raised $54.0M in total across 2 funding rounds.
Protagonist Therapeutics's investors include Canaan Partners, Aberdare Ventures, Johnson & Johnson Innovation, Pivotal bioVenture Partners.
Key people at Protagonist Therapeutics.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company specializing in peptide drug discovery and development to address unmet needs in rare and prevalent diseases, such as blood cancers, ulcerative colitis, polycythemia vera, and inflammatory bowel diseases.[1][2] The company engineers peptide and small molecule compounds that mimic or inhibit key protein interactions, targeting challenging biological pathways like cytokines, receptors, integrins, and transporters, with a robust late-stage pipeline including rusfertide for polycythemia vera and PN-493 for inflammatory bowel disease, supported by partnerships like Janssen Biotech.[2] It serves patients with limited treatment options, solving problems of inadequate therapies through first- and best-in-class peptide therapeutics that offer improved potency, specificity, solubility, stability, and manufacturability.[1][2]
Protagonist Therapeutics emerged as a biotech innovator leveraging a proprietary peptide technology platform to tackle diseases where conventional treatments fall short, though specific founding details like year or founders are not detailed in available sources.[1][2] The company's idea stems from advancing peptide engineering tools and methods to create novel agonists and antagonists for hard-to-drug targets, leading to early pipeline development in blood disorders and inflammatory conditions.[2] Pivotal moments include building a late-stage portfolio with significant market potential and securing co-development partnerships, such as with Janssen Biotech, which accelerated progress toward clinical advancements like rusfertide and PN-493.[2]
Protagonist rides the wave of peptide therapeutics as a transformative modality in biotech, bridging the gap between biologics and small molecules to address "undruggable" targets in oncology, immunology, and rare diseases amid rising demand for precision medicines.[2] Timing aligns with advances in peptide engineering and a surge in inflammatory disease prevalence, bolstered by market forces like partnerships with big pharma (e.g., Janssen) that de-risk development and expand access.[2] The company influences the ecosystem by pioneering first-in-class treatments, educating on diseases like polycythemia vera, and fostering scientific exchange, potentially reshaping standards for blood disorders and IBD therapies.[2][4]
Protagonist is poised to advance its late-stage candidates toward approval, with rusfertide and PN-493 targeting blockbuster opportunities in polycythemia and IBD, potentially amplified by ongoing Janssen collaborations.[2] Trends like AI-driven peptide design and personalized medicine will shape its trajectory, enabling faster iteration on novel targets. Its influence may evolve from pipeline innovator to ecosystem leader in peptide-based therapies, delivering life-changing options for underserved patients and reinforcing its mission from the outset.[1][2]
Protagonist Therapeutics has raised $54.0M across 2 funding rounds. Most recently, it raised $40.0M Series C in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $40.0M Series C | Canaan Partners | |
| Jun 1, 2013 | $14.0M Series B | Aberdare Ventures, Johnson & Johnson Innovation, Pivotal bioVenture Partners |
